icon person with stethoscope and dog

Animal health professionals

On this page, you will find information on the European Medicines Agency’s (EMA) activities, including news and events, that are most relevant to Animal health professionals and users of veterinary medicines such as pet owners.

You can contribute to EMA's work by responding to our public consultations.

Learn more about EMA's Committee for Veterinary Medicinal Products (CVMP) and its role in veterinary medicine regulation in Europe.

Featured information for animal health professionals

CVMP recommends approval of two vaccines against bluetongue disease

EMA’s Committee for Veterinary Medicinal Products (CVMP) recommended the approval of vaccines Bluevac-3 and Syvazul BTV 3 to protect sheep and cattle against the serotype-3 bluetongue virus (BTV3). This virus has been responsible for outbreaks in Europe, where there is a need for effective vaccines against it. Vaccination can control its spread, reduce economic losses, protect livestock trade and prevent animal suffering.

EMA communication activities: 2024 survey results

We asked stakeholders for feedback on our external communication activities via a bi-annual survey disseminated in May 2024. The results are available in a newly-published report. They help us to establish baselines and targets to measure progress, analyse trends and address areas for improvement.

EMA joins EU Partnership on Animal Health and Welfare

EMA has become an associate of the EU Partnership on Animal Health and Welfare, established to help control infectious diseases of both terrestrial and aquatic animals. This partnership also aims to support the global One Health initiative. In this capacity, EMA will strengthen links between research and EU medicines regulation through communication and engagement with researchers and other stakeholders.

Promoting a One Health approach in Europe

EMA and other scientific EU agencies responsible for human, animal health and environmental protection have issued a joint statement on promoting a joined-up One Health agenda in Europe. They identify four priority areas for action.

EMA recommendations to reduce risks to humans and animals from exposure to N-methyl pyrrolidone in veterinary medicines

EMA’s Committee for Veterinary Medicinal Products (CVMP) recommended measures addressing the inconsistencies in the product information of medicines containing the excipient N-methyl pyrrolidone (NMP), which are marketed in the European Union (EU). NMP can cause birth defects in children of women who handle NMP-containing medicines during pregnancy, and in the offspring of animals given these medicines

Stay safe when buying veterinary medicines online

From 28 January 2022, you can check if an online retailer is authorised to sell veterinary medicines in the EU / EEA by looking for the official logo on the retailer's website. Clicking on the logo should open the national register where the retailer is established and registered. Do not continue with your purchase if the retailer is not on the national register.

Latest news

SEE ALL NEWS

Upcoming events

SEE ALL EVENTS

Publications of interest

EMA's 2023 annual report

Navigate through the digital report to view interviews, short videos and an interactive timeline of the Agency’s main activities in 2023. Read the traditional PDF version to see additional figures and statistics on EMA's regulatory procedures and activities.

10-year report on EMA's MUMS / veterinary limited market scheme

Read about the main achievements of EMA's MUMS / veterinary limited market scheme during its period of application. The scheme has since been replaced by specific legal provisions for veterinary limited markets in the Veterinary Medicines Regulation, which came into effect in January 2022.

Share this page

Back to top